IVDs include immunoassays, molecular diagnostics (PCR, NGS), point-of-care tests, hematology, and clinical chemistry. The segment spans high-volume central-lab platforms to consumer at-home tests. Business models range from instrument sales to reagent rental, where recurring consumable revenue funds the installed base. In the US, IVDs are regulated by FDA and test use is governed by CLIA lab categories, while the EU regulates them under the IVDR. Payment is driven largely by the Clinical Laboratory Fee Schedule and private payer policies.

Why it matters

Regulatory shifts (EU IVDR, FDA's LDT rule) and the rise of multi-cancer early detection (MCED) and minimal-residual-disease (MRD) testing are reshaping investment and competitive dynamics.

Common pitfalls

•A common pitfall is misunderstanding the specific classification rules for an IVD, which can lead to incorrect conformity assessment pathways and delays.
•Failing to keep up with evolving regulatory frameworks, such as the EU IVDR transition or new FDA guidance on Laboratory Developed Tests (LDTs), can result in non-compliance.
•Assuming that a device cleared in one jurisdiction will automatically be accepted in another without fulfilling local regulatory requirements is a mistake.
•Neglecting the cybersecurity risks associated with connected IVDs, especially those processing sensitive patient data, can lead to vulnerabilities and data breaches.
•Underestimating the post-market surveillance requirements for IVDs across different regulatory environments can result in inadequate monitoring and reporting.

Sources

AdvaMedDx · AdvaMedDx
MedTech Europe - Facts & Figures · MedTech Europe
MedTech Dive · MedTech Dive
In vitro diagnostics · U.S. Food and Drug Administration (FDA)

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.